Fig. 1



nucleic acid to be detected

complement thereof

Fig. 2



elongation product

elongation product



amplificate

complement of the amplificate



amplificate with tails Y

Fig. 3



Fig. 4


HCV
AGTATGAGTGTCGTGCAGCCTCCAGGACCCCCCCTCCCGGGAGAGCCA
HUMAN
AGTATGTGTGTCGTGCAGCCTCCAGGACCCCCACTCCCGGGAGAGCCA

09/530929 PCT/US98/22850

FIG. 5



FIG 6


HCV
261 5′-GGTACTGCCTGATAGGGTGCTTGCGAGTGCCCCGGGAGGTCTCGTAGACCGTGCACCATGA-3′ 333
Foreward primer CK10/Reverse primer CK20
Foreward primer CK11/Reverse primer CK20
5′-CGTACTGCCTGATAGGGTGCT-3′
5′-CGTACTGCCTGATAGGGTGC-3′
3′-CAGAGMATMTGGMATCGTGTAMG-5′
3′-CAGAGMATMTGGMATMGTGTAMG-5′
Foreward primer CK10-1/Reverse primer CK20-1
Foreward primer CK11-1/Reverse primer CK20-1
5′-CGTACTGCCTIATAGGGTICT-3′
5′-CGTACTGCCTIATAGGGTIC-3′
3′-CDGDIMDTMTGGMATMGTGTAMG-5′
3′-CDGDIMDTMTGGMATMGTGTAMG-5′
Foreward primer CK10-2/Reverse primer CK20-2
Foreward primer CK11-2/Reverse primer CK20-2
5′-CGTAMTGMMTIATAGGGTIMT-3′
5′-CGTAMTGMMTIATAGGGTIM-3′
3′-MDGDIMDTMTGGMAPPKPGTAMG-5′
3′-MDGDIMDTMTGGMAPPKPGTAMG-5′
Foreward primer CK10/Reverse primer CK21
Foreward primer CK10-1/Reverse primer CK21-1
Foreward primer CK11-1/Reverse primer CK21-1
Foreward primer CK10-1/Reverse primer CK21-2
Foreward primer CK11-1/Reverse primer CK21-2
Foreward primer CK10-2/Reverse primer CK21-3
Foreward primer CK11-2/Reverse primer CK21-3
5′-CGTACTGCCTGATAGGGTGCT 3′
5′-CGTAMTGMMTIATAGGGTICT 3′
5′-CGTAMTGMMTIATAGGGTIC 3′
5′-CGTAMTGMMTIATAGGGTICT 3′
5′-CGTAMTGMMTIATAGGGTIC 3′
5′-CGTAMTGMMTIATAGGGTIMT 3′
5′-CGTAMTGMMTIATAGGGTIM 3′
3′-CTTCAGAGCATCTGGCATCGTGTACG-5′
3′-CTTMDGDIMDTMTGGMATMGTGTAMG-5′
3′-CTTMDGDIMDTMTGGMATMGTGTAMG-5′
3′-CTPMDGDIMDTMTGGMATMGTGTAMG-5′
3′-CTPMDGDIMDTMTGGMATMGTGTAMG-5′
3′-MTPMDGDIMDTMTGGMAPPKPGTAMG-5′
3′-MTPMDGDIMDTMTGGMAPPKPGTAMG-5′
HGBV-B
389 5′-CGTACTGCCTGATAGGGTCCTTGCGAGGGGATCTGGGAGTCTCGTAGACCGTAGCACATGC-3′ 449

09/530929

FIG 7





F.primer-GH3: 5`-TCaTCACGCAGAcAGCGTCTAG-3`
R.primer-GH4: 5`-GgTGCACGACAgTCATACTAA-3`

capture probe-GHp2: CTAGCCATGcCGTT
amplicon-size: 51 bp

FIG. 8